Anorectal Cancer in Crohn's Disease Has a Poor Prognosis Due to its Advanced Stage and Aggressive Histological Features: a Systematic Literature Review of Japanese Patients.
Anorectal cancer
Crohn’s disease
Surveillance colonoscopy
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
27
11
2018
medline:
4
11
2020
entrez:
27
11
2018
Statut:
ppublish
Résumé
Patients with Crohn's disease (CD) are generally known to be at an increased risk of cancer. The anorectal area is the most frequent cancer site in Japanese CD patients. However, the risks are not well defined. The aim of this study was to clarify the clinicopathological characteristics of Japanese CD-associated anorectal carcinoma patients and to explore screening methods for the detection of cancer at earlier stages. A systematic review of case series and reports of Japanese CD-associated anorectal cancer patients published between 1983 and 2016 was conducted. There were 144 cases of cancer arising from anorectal lesions of CD. The median duration from the onset of CD to the cancer diagnosis was approximately 17 (0-39) years. The most prevalent histological type of cancer was mucinous carcinoma (49.3%), and 82.1% of patients were over T3 invasion. There were only 15.6% cases with early stage disease. A total of 82% patients had enhanced symptoms, whereas 56.3% of the early cancer cases had no symptomatic changes. Approximately 90% of cases were diagnosed preoperatively, and almost all early cancer patients were diagnosed with colonoscopy. The 5-year overall survival rate was 35.8%. CD-associated anorectal carcinoma had a poor prognosis due to the advanced stage of the cases and aggressive histological features. As earlier-stage cancer is associated with a better prognosis than advanced stage disease, and it is also typically diagnosed by colonoscopy, surveillance colonoscopy may therefore help to improve the prognosis in cases without any symptomatic changes.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with Crohn's disease (CD) are generally known to be at an increased risk of cancer. The anorectal area is the most frequent cancer site in Japanese CD patients. However, the risks are not well defined. The aim of this study was to clarify the clinicopathological characteristics of Japanese CD-associated anorectal carcinoma patients and to explore screening methods for the detection of cancer at earlier stages.
METHODS
METHODS
A systematic review of case series and reports of Japanese CD-associated anorectal cancer patients published between 1983 and 2016 was conducted.
RESULT
RESULTS
There were 144 cases of cancer arising from anorectal lesions of CD. The median duration from the onset of CD to the cancer diagnosis was approximately 17 (0-39) years. The most prevalent histological type of cancer was mucinous carcinoma (49.3%), and 82.1% of patients were over T3 invasion. There were only 15.6% cases with early stage disease. A total of 82% patients had enhanced symptoms, whereas 56.3% of the early cancer cases had no symptomatic changes. Approximately 90% of cases were diagnosed preoperatively, and almost all early cancer patients were diagnosed with colonoscopy. The 5-year overall survival rate was 35.8%.
CONCLUSION
CONCLUSIONS
CD-associated anorectal carcinoma had a poor prognosis due to the advanced stage of the cases and aggressive histological features. As earlier-stage cancer is associated with a better prognosis than advanced stage disease, and it is also typically diagnosed by colonoscopy, surveillance colonoscopy may therefore help to improve the prognosis in cases without any symptomatic changes.
Identifiants
pubmed: 30474795
doi: 10.1007/s12029-018-0180-6
pii: 10.1007/s12029-018-0180-6
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-9Références
Anticancer Res. 2013 Feb;33(2):685-9
pubmed: 23393368
Gut. 1994 Mar;35(3):347-52
pubmed: 8150345
J Gastroenterol Hepatol. 2013 Aug;28(8):1300-5
pubmed: 23488881
Digestion. 2010;81(4):265-70
pubmed: 20134166
J Magn Reson Imaging. 2007 Dec;26(6):1659-62
pubmed: 17968942
Int J Colorectal Dis. 2007 Dec;22(12):1537-42
pubmed: 17717673
Dis Colon Rectum. 2007 Jun;50(6):839-55
pubmed: 17308939
Inflamm Bowel Dis. 2006 Jun;12(6):491-6
pubmed: 16775493
Gastroenterology. 2001 Mar;120(4):820-6
pubmed: 11231935
Gut. 1994 May;35(5):651-5
pubmed: 8200559
Ann Surg. 2012 Apr;255(4):739-46
pubmed: 22395093
J Gastroenterol. 2013 Jan;48(1):31-72
pubmed: 23090001
Digestion. 2016;94(1):24-9
pubmed: 27348311
J Gastroenterol. 2011 Jan;46 Suppl 1:1-5
pubmed: 20798970
J Gastrointest Surg. 2010 Jan;14(1):66-73
pubmed: 19826882
Dis Colon Rectum. 1998 Aug;41(8):992-6
pubmed: 9715154
J Gastroenterol. 2012 Dec;47(12):1308-22
pubmed: 22627504
Gut. 2001 Apr;48(4):526-35
pubmed: 11247898
J Gastroenterol. 2009;44(7):659-65
pubmed: 19424654
Anticancer Res. 2007 Nov-Dec;27(6A):3771-4
pubmed: 17970041
Am J Gastroenterol. 2007 Jan;102(1):163-7
pubmed: 17037994
J Gastroenterol Hepatol. 2008 Nov;23(11):1683-8
pubmed: 18752557
Br J Cancer. 2009 Nov 17;101(10):1671-5
pubmed: 19826420
Int J Colorectal Dis. 2017 May;32(5):661-666
pubmed: 28293746
Aliment Pharmacol Ther. 2006 Apr 15;23(8):1097-104
pubmed: 16611269
Gastrointest Endosc. 2006 Apr;63(4):558-65
pubmed: 16564852
Am J Gastroenterol. 2005 Dec;100(12):2724-9
pubmed: 16393226
Hepatogastroenterology. 2008 Nov-Dec;55(88):2121-4
pubmed: 19260489
Anticancer Res. 2016 Jul;36(7):3761-6
pubmed: 27354651
Dis Colon Rectum. 1992 Sep;35(9):850-6
pubmed: 1511645
Inflamm Bowel Dis. 2011 Mar;17(3):802-8
pubmed: 20848547
Lancet. 1990 Aug 11;336(8711):357-9
pubmed: 1975343
Gastroenterology. 2010 Feb;138(2):746-74, 774.e1-4; quiz e12-3
pubmed: 20141809
Dis Colon Rectum. 2016 Dec;59(12):1168-1173
pubmed: 27824702